XTalks

MAY 5, 2023

This week, the US Food and Drug Administration (FDA) approved the world’s first respiratory syncytial virus (RSV) vaccine. GSK says the RSV vaccine will be available for older adults before this year’s RSV season, which usually starts before the winter months. RSV is a negative-strand RNA virus that was first identified in 1955.

Vaccination 105

Vaccination Vaccine FDA Approval Development 105

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

XTalks

JUNE 5, 2023

Pfizer has announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has received approval from the US Food and Drug Administration (FDA). Abrysvo, the bivalent RSV prefusion F (RSVpreF) vaccine, is intended for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

XTalks

FEBRUARY 24, 2025

Carlsbad, California-based Ionis Pharmaceuticals announced it will be sharing promising new trial data for its RNA-targeted prophylactic treatment donidalorsen for hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, California.

Trials 59

Trials RNA Allergies Drugs 59

XTalks

MARCH 8, 2022

On International Women’s Day, Xtalks is celebrating women’s leadership in the life sciences by highlighting some of the female leaders at the forefront of scientific discovery, as well as the continuing challenges of attaining more equitable representation. Challenges in Women’s Leadership.

Life Science 105

Life Science Gene Therapy DNA Vaccination 105

XTalks

DECEMBER 22, 2021

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

AUGUST 18, 2020

An important feature of the test that contributes to its reduced cost is the fact that sample processing does not require a separate nucleic acid (RNA) extraction step. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

Pharmaceutical Technology

MAY 22, 2023

There is a stark difference in favour of the UK biotech ecosystem in terms of expenses compared to the US biotech ecosystem, and specifically the New England region, says Mark Leuchtenberger, CEO of Oxford-based company SpyBiotech, a vaccine developer that plans to study a human cytomegalovirus infection vaccine in H2 2023.

Marketing 279

Marketing Development Research Scientist 279

XTalks

OCTOBER 21, 2020

In addition, Berrio and colleagues discovered other novel targets of positive selection, namely within genes encoding Nsp4 and Nsp16, which are viral enterotoxins important for the stability of the RNA structure of the virus. Moreover, Berrio says the changes likely affected the folding and function of viral RNA.

RNA 98

RNA Protein Genomics Genome 98

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines. “This is just the beginning; the potential is enormous,” he says.

Genomics 105

Genomics Genome Medicine Development 105

XTalks

DECEMBER 1, 2021

Moreover, it is also not known how the current COVID-19 vaccines and drugs will hold up against Omicron. While most of the current COVID-19 PCR tests involve detection of spike RNA, Cue’s test does not and, instead, is based on identifying RNA encoding the virus’s nucleocapsid proteins.

Gene 105

Gene Genome Genomics Genetics 105

XTalks

MARCH 10, 2021

Along with COVID-19 vaccine authorizations, the US Food and Drug Administration (FDA) remains committed to increasing access to COVID-19 tests and supporting their development, having authorized three new tests recently for emergency use. The products encompass molecular, antigen and T cell-based testing approaches.

Protein 98

Protein RNA Antibody Production 98

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. It was the third approval from Alnylam’s pipeline of RNA interference therapeutics to make it to market.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

XTalks

OCTOBER 8, 2024

In a statement , the Nobel Assembly said the laureates discovered a new class of non-coding RNA molecules that play a crucial role in gene regulation. To activate these instructions, cells create a copy called messenger RNA (mRNA), which exits the nucleus and directs the cell’s machinery to produce a specific protein.

Regulation 52

Regulation Genetics Scientist RNA 52

XTalks

AUGUST 12, 2020

Xtalks spoke to lead author on the study, Mohamed Abdel-Mohsen, PhD, assistant professor, Vaccine & Immunotherapy Center at the Wistar Institute, about the emerging utility of identifying glycomic, or sugar, signatures on the surface of immune cells to help in their identification and potential targeting.

RNA 52

RNA Protein DNA In-Vivo 52

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. Promising HIV Vaccines in Clinical Trials Advancements in preventable therapeutic options for HIV are currently in progress. percent in the placebo group.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

pharmaphorum

JULY 19, 2021

Drugs harnessing the potential of modified RNA, antisense and siRNA oligonucleotides, antibody–drug conjugates and nanomedicines will become as important as today’s ‘small molecule’ drugs, reaching potential market values into the hundreds of billions – if the potential can be realised through innovation support and industry collaboration.

Life Science 52

Life Science Medicine RNA Vaccination 52

pharmaphorum

AUGUST 22, 2022

It’s a naturally occurring process, but you can reprogramme that messenger RNA to do what you want and then put it into the body and use it for a multitude of indications,” Torrance states. When Health Innovation Fund first invested in Moderna, it had one candidate for mRNA use. It could completely change how we treat cancers.”

Gene Therapy 102

Gene Therapy Antibody Gene Medicine 102

XTalks

JUNE 18, 2024

Founded in Baltimore, Maryland, a vibrant science hub, Elixirgen Therapeutics emerged from a vision to harness the untapped potential of mRNA technology. In a field quickly gaining attention for its role in vaccine development and personalized medicine, Elixirgen Therapeutics stands out through its pursuit of innovation and safety.

Protein 52

Protein RNA Genetics Gene Expression 52

XTalks

MARCH 23, 2022

The editorial team also learned about Alnylam Pharmaceuticals’ lawsuits against mRNA COVID-19 vaccine makers Pfizer and Moderna over patent infringements. Alnylam claims it invented the lipid nanoparticle delivery technology used in the vaccines and is seeking “fair compensation” for its use.

Life Science 52

Life Science RNA Vaccination Vaccine 52

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. vaccine, mRNA-1273.815.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

JANUARY 5, 2022

In the first episode of 2022, Ayesha provided updates on Omicron and COVID-19 vaccine boosters. Ayesha also discussed some of the predicted trends in the life sciences for 2022. Read the full articles here: FDA Authorizes COVID-19 Vaccine Booster for 12- to 15-Year-Olds, Shortens Booster Interval.

Life Science 52

Life Science RNA Vaccination Vaccine 52

XTalks

MARCH 21, 2022

Credited as a pioneering RNA interference (RNAi) therapeutics company, Alnylam Pharmaceuticals is taking Pfizer and Moderna to court, claiming that the companies’ use of the lipid nanoparticle (LNP)-based RNA delivery technology in their mRNA COVID-19 vaccines infringes on a patented technology.

RNA 98

RNA Vaccination Vaccine Sales 98

The Pharma Data

DECEMBER 8, 2020

Curexsys is founded by Herbert Stadler, a serial biotech entrepreneur, and Jens Gruber, a former group leader of Medical RNA Biology who is going to lead Curexsys as Chief Scientific Officer. ABOUT SARTORIUS The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry.

Manufacturing 52

Manufacturing Containment Life Science Production 52

The Pharma Data

FEBRUARY 25, 2022

“The SARS-CoV-2 vaccines target the spike protein, but this protein is under strong selection pressure and, as we have seen with Omicron, can undergo significant mutations,” said Joyce Jose, assistant professor of biochemistry and molecular biology, Penn State. ” The findings published today (Feb.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. mRNA’s potential for rapid vaccine delivery.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

XTalks

JUNE 20, 2022

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

XTalks

SEPTEMBER 15, 2021

With RNA being the popular new “it” molecule in genetic research, Ayesha discusses Eli Lilly’s new partnership with biotech company ProQR to develop RNA-based therapeutics in this episode. billion deal will see Lilly leverage ProQR’s proprietary RNA editing platform to develop targets of interest.

RNA 40

RNA Life Science Development Genetics 40

XTalks

AUGUST 2, 2023

In a world where health is paramount, the pharmaceutical industry stands as a formidable pillar, relentlessly pursuing scientific breakthroughs and life-saving innovations. With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

JANUARY 10, 2025

Zhengye Biotechnology Holding Limited, a China-based veterinary vaccine manufacturer, closed its initial public offering (IPO) on January 8, 2025, raising $6 million. Specifically, the swine vaccines market was projected to grow from $2.01 billion in 2023 to $2.20

Vaccination 105

Vaccination Vaccine RNA Production 105

XTalks

MAY 29, 2024

In 2023, Merck officially became the proud owner of the world’s best-selling drug Keytruda, which knocked Pfizer’s COVID-19 vaccine Comirnaty from the top spot. The company’s HPV vaccine Gardasil also had robust global demand in 2023, especially in China according to Merck, as well as public-sector buying patterns in the US.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccination 52

XTalks

DECEMBER 24, 2020

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it. Here is a review of what 2020 served up.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

JANUARY 6, 2025

From leveraging artificial intelligence (AI) to streamline diagnostics and treatments to exploring the untapped potential of RNA-based therapeutics, biotechnology is shaping the future of healthcare and beyond. As of January 31, 2024, approximately 131 unique RNA-based therapies are in clinical development across various therapeutic areas.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

XTalks

FEBRUARY 11, 2025

From breakthrough HIV therapies to vital vaccines addressing COVID-19, human papillomavirus (HPV) and other life-threatening infections, these products not only underscore advances in clinical efficacy but also highlight strategic market positioning. Comirnaty (COVID-19 Vaccine, mRNA) Comirnaty 2023 sales: $11.22

Sales 66

Sales FDA Approval Vaccination Vaccine 66

XTalks

MARCH 25, 2025

The development of mRNA vaccines has revolutionized the field of immunization, offering a rapid, adaptable and effective approach to combating infectious diseases. Characterizing mRNA vaccines involves evaluating molecular integrity, purity, potency and immunogenicity, as well as ensuring consistent large-scale production.

Vaccination 59

Vaccination Vaccine Immune Response RNA 59